Neurocrine Biosciences IncNASDAQ:NBIX
- LAST PRICE126.2350
- TODAY'S CHANGE (%)-0.3550 (-0.2804%)
- Bid / Lots126.0500/ 6
- Ask / Lots126.2500/ 6
- Open / Previous Close126.1500 / 126.5900
- Day Range
- 52 Week Range
- Volume143,946
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBIX |
|---|---|---|
| 09:32 ET | 3207 | 126.39 |
| 09:33 ET | 300 | 126.425 |
| 09:35 ET | 200 | 126.425 |
| 09:37 ET | 100 | 127.03 |
| 09:42 ET | 1450 | 125.97 |
| 09:44 ET | 650 | 125.97 |
| 09:46 ET | 107 | 125.98 |
| 09:48 ET | 100 | 125.87 |
| 09:50 ET | 200 | 126.05 |
| 09:51 ET | 200 | 125.88 |
| 09:53 ET | 200 | 125.84 |
| 09:55 ET | 100 | 125.72 |
| 10:00 ET | 1560 | 125.755 |
| 10:02 ET | 300 | 125.6 |
| 10:04 ET | 1400 | 125.795 |
| 10:06 ET | 100 | 125.6813 |
| 10:08 ET | 300 | 125.5 |
| 10:09 ET | 165 | 125.577 |
| 10:11 ET | 11623 | 125.87 |
| 10:13 ET | 400 | 125.94 |
| 10:15 ET | 200 | 125.88 |
| 10:18 ET | 13400 | 126 |
| 10:20 ET | 5148 | 126 |
| 10:22 ET | 1400 | 126.21 |
| 10:27 ET | 3890 | 126.27 |
| 10:29 ET | 900 | 126.11 |
| 10:31 ET | 2519 | 126 |
| 10:33 ET | 1763 | 126.05 |
| 10:36 ET | 1329 | 126.08 |
| 10:38 ET | 3013 | 126.11 |
| 10:40 ET | 370 | 126.18 |
| 10:44 ET | 841 | 126 |
| 10:45 ET | 100 | 126.04 |
| 10:47 ET | 825 | 126.1 |
| 10:49 ET | 3413 | 126.195 |
| 10:51 ET | 1008 | 126.48 |
| 10:54 ET | 594 | 126.5185 |
| 10:56 ET | 4674 | 126.27 |
| 10:58 ET | 255 | 126.37 |
| 11:00 ET | 100 | 126.29 |
| 11:02 ET | 1000 | 126.29 |
| 11:03 ET | 776 | 126.23 |
| 11:05 ET | 100 | 126.28 |
| 11:07 ET | 100 | 126.375 |
| 11:09 ET | 102 | 126.23 |
| 11:14 ET | 674 | 126.2 |
| 11:16 ET | 3029 | 126.32 |
| 11:18 ET | 500 | 126.425 |
| 11:21 ET | 1106 | 126.48 |
| 11:23 ET | 725 | 126.64 |
| 11:25 ET | 550 | 126.5009 |
| 11:27 ET | 200 | 126.55 |
| 11:30 ET | 100 | 126.46 |
| 11:32 ET | 300 | 126.3 |
| 11:34 ET | 857 | 126.245 |
| 11:36 ET | 1640 | 126.18 |
| 11:38 ET | 600 | 126.16 |
| 11:39 ET | 2867 | 126.14 |
| 11:41 ET | 2013 | 126.25 |
| 11:43 ET | 108 | 126.36 |
| 11:45 ET | 2130 | 126.235 |
Nov 26, 2024
Neurocrine Biosciences to Participate at Investor Conferences in December, from 4:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 7, 2024
Nov 5, 2024
Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
8:30AM ET on Monday Nov 04, 2024 by Dow JonesNeurocrine Biosciences Presents New Data on INGREZZA(R) (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia, from 8:25AM ET on Monday Nov 04, 2024 by Dow Jones
8:25AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurocrine Biosciences Inc | 13.0B | 33.8x | +62.04% |
Medpace Holdings Inc | 10.4B | 30.0x | +35.10% |
Exelixis Inc | 10.4B | 23.4x | -21.77% |
Qiagen NV | 9.7B | 106.9x | +12.66% |
BioMarin Pharmaceutical Inc | 12.4B | 39.5x | --- |
Sarepta Therapeutics Inc | 12.5B | 110.8x | --- |
Company Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Contact Information
- Headquarters
- 6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
- Phone
- 858-617-7600
- Fax
- 858-617-7602
Executives
- Non-Executive Independent Chairman of the Board
- William Rastetter
- President, Chief Executive Officer, Director
- Kyle Gano
- Chief Financial Officer
- Matthew Abernethy
- Chief Human Resource Officer
- Julie Cooke
- Chief Scientific Officer
- Jude Onyia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.0B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 101.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $3.73 |
Book Value | $22.61 |
P/E Ratio | 33.8x |
Price/Sales (TTM) | 5.8 |
Price/Cash Flow (TTM) | 31.5x |
Operating Margin | 25.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
